You can buy or sell AXGT and other stocks, options, ETFs, and crypto commission-free!
Axovant Gene Therapies Ltd. Common Shares, also called Axovant Gene Therapies, is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Read More Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.
London, London & South East
52 Week High
52 Week Low
— per share